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There is ample epidemiologic evidence for an association of
chronic hepatitis C virus (HCV) infection with B-cell non-Hodgkin
lymphoma (B-NHL). B-NHL subtypes most frequently associated
with HCV are marginal zone lymphoma and diffuse large B-cell
lymphoma. The most convincing evidence for a causal relation-
ship between HCV infection and lymphoma development is the
observation of B-NHL regression after HCV eradication by antivi-
ral therapy (AVT). In fact, for indolent HCV-associated B-NHL,
ﬁrst-line AVT instead of standard immune-chemotherapy might
be considered. Molecular mechanisms of HCV-NHL development
are still poorly understood. Three general theories have emerged
to understand the HCV-induced lymphomagenesis: (1) continu-
ous external stimulation of lymphocyte receptors by viral anti-
gens and consecutive proliferation; (2) HCV replication in B
cells with oncogenic effect mediated by intracellular viral pro-
teins; (3) permanent B-cell damage, e.g., mutation of tumor sup-
pressor genes, caused by a transiently intracellular virus (‘‘hit and
run’’ theory). This review systematically summarizes the data on
epidemiology, interventional studies, and molecular mechanisms
of HCV-associated B-NHL.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Over 180 million people worldwide are chronically infected with
the hepatitis C virus (HCV), a hepatotropic and potentially lym-
photropic virus [1,2]. HCV infection frequently leads to chronic
hepatitis and is a major cause for liver cirrhosis and its sequelae
such as hepatocellular carcinoma (HCC) [3]. Hematological man-
ifestations such as type II mixed cryoglobulinemia (MC) or B-cell
non-Hodgkin lymphoma (B-NHL) are less common. A large bodyJournal of Hepatology 20
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NHL. Epidemiologic studies, therapeutic approaches, and experi-
mental data gathered in the last two decades established not
only the mere association of viral infection and tumor develop-
ment, but suggest also a causal relationship; e.g., sequencing of
the IgM heavy chain of patients with MC with and without B-
NHL showed clonal B-cell expansion in 100% of HCV infected
individuals in the peripheral blood [4] and, to some extent, in
the liver [5]. The most compelling argument for a causal relation-
ship between HCV and B-NHL is made by interventional studies
demonstrating that a sustained virologic response (SVR) to anti-
viral treatment containing interferon alfa induced regression of
HCV-associated lymphomas and a viral relapse after initial viro-
logic response led to lymphoma recurrence [6,7]. The mecha-
nisms by which HCV may contribute to lymphoma
development are still poorly understood, but considerable data
on the molecular signature of HCV associated B-NHLs (HCV-
NHL) has been gathered.Epidemiology
Pozzato et al. [8] and Ferri et al. [9] were the ﬁrst to describe the
association of HCV and NHL. The initial interest to study this
coincidence was driven by the known high prevalence of HCV
in patients with MC.
Cryoglobulins are immunoglobulins (Igs) in the serum which
precipitate at temperatures below 37 C. Type II MC is character-
ized by a combination of monoclonal and polyclonal Igs with a
monoclonal IgM component often directed against IgG (rheuma-
toid factor activity). HCV antigens (e.g., HCV core protein) and
HCV RNA have been found enriched in the formed immune com-
plexes [10]. Moreover, a very high prevalence of HCV (close to
100%) was found in type II MC patients [11]. While only a minor-
ity of the HCV positive population experiences symptomatic MC
(e.g., MC-vasculitis), the prevalence of low level circulating cryo-
globulins reaches up to 50% of the infected patients [12]. Epide-
miologic studies on HCV-MC show large differences in the
geographic distribution, with higher prevalence in Southern
Europe compared with Northern Europe or USA. Notably, the
presence of MC in HCV positive patients may increase the risk
to develop NHL. An Italian multicenter study showed an over13 vol. 59 j 169–177
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35-fold increased risk to develop NHL for HCV positive patients
with symptomatic MC compared with the general population
[13] and consecutively, approximately 8–10% of patients with
HCV-MC progress to overt NHL. Even after HCV eradication,
HCV-MC patients may remain at high risk to develop a B-NHL
[14].
Compared to the high association rate of HCV infection with
HCC, epidemiologic studies on the relationship between HCV
and NHL show a rather moderate risk for lymphoma develop-
ment (odds ratios between 2 and 3 on average). Especially in
the early case-control studies conducted in the ‘90s, the strength
of association greatly varies, with increased odds ratios (OR) in
countries with high HCV prevalence, e.g., Italy, Egypt, Japan or
southern US regions (prevalence >2%) and lower to no evident
correlation in low prevalence countries such as Scandinavia, UK
or northern US regions and Canada (prevalence 0.01–0.1%) [15].
In France, where HCV prevalence is intermediate (0.7–1%), no evi-
dence for an excess in B-NHL prevalence could be shown [16]. In
Europe, in particular, these data seem to reﬂect a known north-
south slope of HCV prevalence. Different theories have been sug-
gested to explain the geographic differences in the association of
HCV with B-NHL: (1) a difference in the HCV carrier population
with northern European countries depending highly on transmis-
sion via intravenous drug use (IVDA), while the south of Europe
features a combination of older HCV positive patients with iatro-
genic transmission and younger patients with history of IVDA. (2)
A population with long-lasting infection in the south versus a
population with more recent infection (e.g., via IVDA) in the
low prevalence countries, thus not allowing full consequences
of malignant transformation to become evident. (3) Known geo-
graphic differences in the HCV genotype distribution could play
a role, as association of NHL development with certain HCV geno-
types has been reported [17], although such correlation with
genotypes was not shown for HCV-MC. (4) Studies in low-preva-
lence countries may not have included enough patients to ade-
quately detect the association. Notably, several studies in low-
prevalence countries nevertheless showed a signiﬁcant associa-
tion of HCV and B-NHL [18,19]. Efforts have been made to a sys-
tematic approach including several meta-analyses (Table 1).
Although those studies all demonstrate signiﬁcant association
of HCV with B-NHL, there are varying results concerning the
degree of increased NHL risk. The ﬁrst systematic review and
meta-analysis (including 5542 patients and 48 studies) was con-
ducted in 2003 by Gisbert et al. [15], identifying a mean HCV
infection prevalence within the NHL group of 13%. In 10 exam-
ined case-control studies, HCV prevalence in NHL vs. healthy con-
trols was 17% vs. 1.5%, respectively (odds ratio 10.8). Another
subsequent meta-analysis including data from 4049 NHL patients
and 1,813,480 controls conﬁrmed such a high strength of associ-
ation (OR 5.7) [20]. An updated meta-analysis, which not only
included case-control designs but also prospective cohort studies,
found only moderately increased relative risk (RR) for lymphoma
development in HCV positive patients [21]. Pooled RR for HCV-
NHL was 2.5 (95% conﬁdence interval [CI], 2.1–3.1) in case-con-
trol settings and 2.0 (95% CI, 1.8–2.2) in cohort studies. Recently,
one of the largest cross-sectional studies from the US presented
the analysis of ICD-9 discharge diagnoses for coincidence of
HCV and NHL, incorporating a total of 1,055,912 patients’ dis-
charges. Again a signiﬁcant association was demonstrated [22].
Throughout most meta-analyses, again, a high geographic heter-
ogeneity becomes evident, with high OR in endemic countries170 Journal of Hepatology 201compared to low-prevalence regions. Indeed, the fraction of
NHL attributable to HCV may be as high as 10% where HCV prev-
alence is high [21].
The question as to which subtypes of B-NHL are most closely
associated to HCV still remains a matter of debate. The B-NHL
subtypes most frequently described as being associated with
HCV are marginal zone lymphomas (MZL), in particular splenic
marginal zone lymphomas (SMZL), lymphoplasmacytic lym-
phoma (LPL), and diffuse large B-cell lymphoma (DLBCL) [23].
One meta-analysis did not ﬁnd any subtype speciﬁc association
[21], which may be attributable to a lack in the number of
well-matched cases and controls. In a large European multicenter
case-control study (Epilymph), DLBCL, MZL, and LPL were identi-
ﬁed as most closely related to HCV infection, however, those sub-
groups consisted of relatively few cases [24]. Consecutively, a
worldwide approach by the International Lymphoma Epidemiol-
ogy Consortium (Interlymph) pooled data of seven previous sur-
veys with matched cases and controls, demonstrating an overall
OR of 1.78 (95% CI 1.4–2.3). In the subtype speciﬁc analysis,
HCV infection was associated with MZL (OR 2.47), DLBCL (OR
2.24), and LPL (OR 2.57) [25]. Notably, one large multicenter
case-control study from Italy found a higher OR for aggressive
vs. indolent lymphoma types and speculated that previous data
might have been biased by shorter overall survival rates of
aggressive lymphomas [26].Interventional studies (antiviral therapy of HCV-B-NHL)
Treatment of indolent HCV-NHL
The association of HCV and B-NHL has been well established by
aforementioned epidemiologic trials. But still, the most convinc-
ing evidence for a causal relationship between HCV infection
and lymphoma development is the observation of B-NHL regres-
sion after HCV eradication by AVT. While of anecdotal character
in the late ‘90s [27], the concept of antiviral treatment of HCV-
NHL was ﬁrmly established by Hermine et al. in 2002, who suc-
cessfully treated splenic lymphoma with villous lymphocytes
with interferon (IFN)-alfa monotherapy [7]. Of nine treated
patients, the investigators observed durable lymphoma remission
in all patients (seven) with viral clearance under IFN-therapy. The
two remaining HCV-NHL patients were consecutively treated
with IFN and additional ribavirin (RBV), which led to viral as well
as oncologic response. Importantly, six equally treated NHL
patients without HCV infection showed no lymphoma response.
Similar results were consecutively reproduced by the same group
and others, as summarized in Table 2. Throughout these various
works, lymphoma regressionwas closely correlatedwith a decline
in viral load under AVT. In 2004, two studies reported lymphoma
regression under AVT with combination therapy with IFN-alfa 2b
and RBV, including mucosa-associated lymphoid tissue (MALT)
lymphomas and SMZL, disseminated MZL as well as MALT lym-
phomas, respectively [28,29]. In both studies, complete hemato-
logic response was closely correlated with virological response.
With availability of pegylated (Peg)IFN also the standard treat-
ment for HCV-NHL was adapted. Mazzaro et al. [30] compared
pegylated and standard IFN in combination with RBV as ﬁrst-line
treatment in 18 HCV-NHL patients (16 of 18 LPL). Achievement of
sustained virological response (SVR) was higher in the PegIFN
group, which consecutively led to higher lymphoma remission3 vol. 59 j 169–177
Table 1. Summary of meta-analyses on HCV associated lymphoma.
Meta-analyses Year Cases included Included studies OR/RR Subtype association
Gisbert et al., [15]* 2003 5542 48 OR 10.8 (7.4-16) LPL
Matsuo et al., [20] 2004 4049 23 OR 5.7 (4.09-7.96) n.a.
Dal Maso et al., [21]+ 2006 4678 18/15 RR 2.5 (2.1-3.0) none found
De Sanjose et al., [25]§ 2008 4784 7 OR 1.78 (1.4-2.3) LPL, MZL, DLBCL
MZL, marginal zone lymphoma; LPL, lymphoplasmacytic lymphoma; DLBCL, diffuse large B-cell lymphoma; n.a., not available.
⁄1st systematic review/meta-analysis.
+Combination of case-control designs and prospective cohort studies.
§Pooled analysis (no meta-analysis).
JOURNAL OF HEPATOLOGYrates, as SVR was associated with complete hematological
response in all cases. While most of the studies focused on certain
lymphoma entities, such as SMZL, also other indolent lymphoma
subtypes have been successfully treated with AVT. Vallisa et al.
[31] treated a variety of different indolent HCV-NHL (4 SMZL, 2
nodal MZL, 2 extranodal MALT-lymphomas, 4 LPL, 1 follicular
lymphoma) with PegIFN and RBV. Of twelve assessable patients,
seven achieved complete response and 4 partial response or stable
disease, with only one patient experiencing disease progression.
Again, lymphoma response (complete or partial, 75%) was signif-
icantly associated with decline in HCV viral load.
Of note, there is a study, which impressively demonstrates
clinically that HCV likely triggers B-NHL. Paulli et al. [32] report
on two patients with HCV-associated ‘‘lipoma-like’’ extranodal
MZL treated with AVT. One patient showed virologic as well as
hematologic response. The other patient, who received AVT as
second-line therapy after relapse to prior conventional radio-che-
motherapy, became HCV-RNA negative under AVT with concom-
itant complete lymphoma remission. Eight months after stopping
AVT, the patient showed virologic relapse and another three
months later also experienced lymphoma recurrence.Treatment of aggressive HCV-NHL
In the management of HCV-associated aggressive B-NHL, mainly
DLBCL, anthracycline-based chemotherapy coupled with ritux-
imab (immuno-chemotherapy) remains the standard of care,
while AVT, to date, does not play a signiﬁcant role. Firstly, in
the treatment of aggressive lymphoma subtypes, current antiviral
regimens take too long to unfold intended antitumoral effects
and secondly, highly malignant HCV-NHL are likely not exclu-
sively antigen driven, but may have acquired additional onco-
genic mutations. Nevertheless, there are few anecdotal reports
that even showed successful AVT of DLBCL [33,34] or mantle cell
lymphoma [35]. But even when treating aggressive HCV-NHL
with standard immuno-chemotherapy, the underlying HCV infec-
tion still remains an issue to be considered. After remission of the
lymphoma, it seems intuitive to eradicate HCV to prevent recur-
rence. Concurrent chemo and antiviral therapy is primarily ham-
pered by hematological toxicity, but sequential immuno-
chemotherapy followed by AVT has been used in two studies
with promising results, leading to improved clinical outcome
and prolonged disease free survival [36,37]. More and preferably
prospective data, including the use of the emerging direct acting
antiviral therapies for HCV, are needed at this point.
Another important clinical issue is the inﬂuence of chronicHCV
infection on immuno-chemotherapy of HCV-NHL. Side-effect pro-
ﬁle and efﬁcacy of standard treatment seem to be negativelyJournal of Hepatology 201affected by underlying viral disease [38,39]. Rituximab, as an
important modern pillar of NHL therapy, may complicate treat-
ment due to added hepatotoxicity and the issue of HCV reactiva-
tion or acceleration of viral liver inﬂammation. Rituximab
therapy inHCV-associatedMChas been demonstrated to be highly
effective. Moreover, rituximab as monotherapy or in combination
with PegIFN and RBV shows good safety and tolerability in treat-
ment of MC, including a lack of viral ﬂares or worsening of viremia
[40–42]. In the treatment of overt HCV-associated lymphoma,
application of anthracycline-based chemotherapy coupled with
rituximab or concomitant immuno-chemotherapy and AVT shows
a less beneﬁcial safety proﬁle, includinghematological toxicity and
hepatic ﬂares. Different mechanisms have been proposed to
explain higher rates of liver dysfunction and worse outcomes of
standard chemotherapy in HCV-NHL [39,43]: (1) aggravation of
preexisting liver damage due to HCV; (2) accelerated HCV replica-
tion and concomitant liver damage; (3) hepatitis due to post-treat-
ment immune reactivation; and (4) increased drug toxicity from
altered drug metabolism. While prophylactic HBV therapy during
chemotherapy is standard of care, concomitant HCV treatment is
not feasible, asmentionedabove.Whether rituximabcauses added
negative impact on hepatotoxicity is still amatter of debate as only
few systematic comparative data exist [44]. Treatment of HCV-
NHL should be performed in an interdisciplinary approach with
hepatologists and hematologists working hand in hand with close
monitoring of liver function, as dose adjustment or stopping of
treatment has shown to translate into worsening of overall sur-
vival [38]. For the future, there are high expectations towards the
new standard of care in HCV therapy consisting of a triple therapy
with a protease inhibitor (boceprevir or telaprevir) in addition to
PegIFN and RBV [45,46]. As stated above, lymphoma response for
treatment of HCV-NHL is closely related to achievement of SVR.
Low rates of SVR under IFN and RBV therapy for HCV, especially
in genotype 1 patients, have been one of themajor hampering fac-
tors to choose AVT over standard immuno-chemotherapy in HCV-
NHL. With improved SVR rates under the new standard of HCV
therapy, also higher oncological response rates in HCV-NHL may
be expected. Other advantages of the newly approved triple ther-
apy aswell as upcomingHCV-AVT are shortened durations of ther-
apy [47]. This fact couldbeparticularly interesting in the therapyof
lymphoma patients who need prompt therapy (e.g., symptomatic
disease or even aggressive HCV-NHL). Finally, the lack of severe
IFN-associated hematotoxic effects in upcoming IFN-free HCV
treatment regimens might be a great improvement in HCV-NHL
therapy [48]. Abandonmentof IFNwould removeadditional hema-
tological toxicity on top of the one caused by the underlying lym-
phoma. In the combination of immuno-chemotherapy and AVT, a
reductionof hematotoxicity could signiﬁcantly improve treatment
tolerability. Furthermore, there may still remain some doubt on3 vol. 59 j 169–177 171
Table 2. Studies of antiviral treatment in patients with HCV-associated lymphoma.
N° pts* Antiviral treatment Diagnosis MC Virologic response NHL response
Patriarca et al., [93] 1 IFNα LPL - 1 1 CR
Casato et al., [94] 1 IFNα MZL 1 HCV-RNA decrease 1 CR
Caramaschi et al., [95] 1 IFNα MZL/MALT - n.a. 1 CR
Bauduer [96] 1 IFNα MZL/MALT - 1 1 PR
Pitini et al., [97] 2 IFNα SMZL - 2 2 CR
Moccia et al., [98] 3 IFNα SMZL - n.a. 2 CR
Hermine et al., [7] 9 IFNα SLVL 6 7 7 CR
Kelaidi et al., [28] 8 IFNα + RBV SMZL (n = 4), 
MZL/MALT (n = 4)
8 5 SVR, 2 NSVR 5 CR
Tursi et al., [29] 16 IFNα + RBV MZL/MALT - 11 16 CR
Saadoun et al., [99] 18 IFNα (n = 8)
IFNα + RBV (n = 10)
SLVL 18 14 CR, 4 NSVR 14 CR, 4 PR
Mazzaro et al., [30] 18 IFNα + RBV (n = 8)
PegIFNα + RBV (n = 10)
SLVL (n = 1), FL (n = 1),  
LPL (n = 16)
13 3 SVR, 4 NR, 1 NSVR
6 SVR, 2 NR, 2 NSVR
3 CR, 2 PR
6 CR, 2 PR
Oda et al., [100] 1 PegIFNα + RBV B-NHL (liver) - SVR CR
Mauro et al., [101] 1 PegIFNα + RBV LPL 1 SVR CR
Takahashi et al., [102] 1 PegIFNα + RBV NLPHL - SVR CR
Svoboda et al., [103] 1 PegIFNα + RBV MZL/MALT - 1 CR
Paulli et al., [32] 2 PegIFNα + RBV MZL/MALT 2 2 CR 1 CR, 1 PR
Pellicelli et al., [34] 9 PegIFNα + RBV SMZL (n = 3), 
MZL (n = 4), FL (n = 2)
4 7 SVR, 2 NSVR 5 CR, 2 PR
Vallisa et al., [31] 13 PegIFNα + RBV SMZL (n = 4), 
MZL/MALT (n = 4),  
FL (n = 1), LPL (n = 4)
5 7 SVR, 1 NSVR 7 CR, 2 PR
MC, type II mixed cryoglobulinemia; MZL, marginal zone lymphoma; SMZL, splenic marginal zone lymphoma; SLVL, splenic lymphoma with villous lymphocytes; FL,
follicular lymphoma; LPL, lymphoplasmacytic lymphoma; NHL, non-Hodgkin lymphoma; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma; IFN, interferon;
RBV, ribavirin; CR, complete response; PR, partial response; SVR, sustained virologic response; NSVR, non-sustained virologic response; n.a., not available.
⁄Patients with indolent lymphoma who actually received AVT.
Reviewthe effects of AVT in HCV-NHL, considering the fact that IFN has
also antilymphoproliferative properties. IFN-free regimen eventu-
ally able to achieve NHL regression could prove that virus suppres-
sion has indeed antilymphoma activity. Corresponding new
studies are needed and again, the necessity of an interdisciplinary
approach has to be emphasized, as these new antiviral drugs come
with new side effects, potential drug-drug-interactions and
require close monitoring.Pathomechanisms and molecular signature of HCV-B-NHL
While hepatocytes are themain reservoir and replication space for
the virus, HCV is also potentially lymphotropic [49]. Indeed, the
lymphoid compartment is thought to be a ‘‘viral hideout’’ possibly
allowing for persistence of the virus after seemingly successful
treatment and selection of viral subtypes with altered ﬁtness,
e.g., towards AVT [50,51]. Asmentioned above, there is robust clin-
ical data to suggest a causal relationship between HCV and B-NHL
development. However, knowledge of the molecular mechanism
of HCV-associated lymphomagenesis is still limited. Three general
theories have emerged to understand the HCV-induced transfor-
mation process: (1) Continuous external stimulation of lympho-
cyte receptors by viral antigens and consecutive proliferation; (2)
HCV replication inB cellswithoncogenic effectsmediatedby intra-
cellular viral proteins; (3) permanent B-cell damage, e.g., mutation
of tumor suppressor genes, caused by a transiently intracellular
virus – the so called ‘‘hit and run’’ theory (Fig. 1).
The concept of external antigenic stimulation of lymphocytes/
lymphoma cells has a close similarity to Helicobacter pylori172 Journal of Hepatology 201induced MALT lymphoma development. The compatibility with
clinical ﬁndings of lymphoma remission when the antigen is
removed by AVTmakes this theory appealing. Moreover, clinically
themost frequently associated subtypes of HCV-NHL are of germi-
nal center or post germinal center origin, with antigens posing as
the primary proliferation trigger [52]. However, there is also
experimental data supporting this theory. The HCV envelope pro-
tein E2 binds to CD81 expressed on B cells [53], a receptor that is
upregulated in HCV infection and MC and that is positively corre-
lated with viral load [54]. CD81 is known to form a co-stimulatory
complex with CD19 and CD21 on B cells. Stimulation of CD19/
CD21/CD81 and the B-cell receptor (BCR) leads to a decrease in
B-cell activation threshold and may induce proliferation [55,56].
In fact, binding of HCV E2 together with an antibody against
CD81 on naïve human B cells leads to activation of the JNK path-
way and consecutive proliferation [57]. Furthermore, HCV-NHL
were found to have restricted combinations of HLA class II genes.
The DR5-DQ3 HLA combination was associated with HCV-NHL
patients with MC and DR1-DQ-1 in MC negative HCV-NHL [58],
while DR11was associatedwith HCV-MC [59]. The possibility that
HCV or parts of the virus might pose as the very antigen leading to
B-cell proliferation and development of MC and B-NHL is sup-
ported by different studies. Marasca et al. sequenced clonal immu-
noglobulin variable regions from HCV-NHL patients. Three out of
ﬁve HCV-associated nodal MZLs, showed the usage of the VH1-69
gene with similar CDR3, demonstrating highly biased and non-
random use of the VH segments [60]. Other groups found
restricted expression of VH and VL (VH1-69, VkappaA27) genes as
well as somatic hypermutation in patients with MC or HCV-NHL
[61,62]. Therefore, it can be speculated on an exposure to a3 vol. 59 j 169–177
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Fig. 1. Different theories have been proposed to explain the mechanism of
HCV induced lymphomagenesis. (A) Continuous external stimulation of lym-
phocyte receptors (CD19, CD21, CD81, B-cell receptor [BCR]) by viral antigens and
consecutive proliferation. Evidence of upregulation of oncogenic signals (IL-6,
BLyS), downregulation of tumor suppressive signals (miR-26b), or increase of
somatic hypermutation (SHM). (B) HCV replication inside B cells with oncogenic
effects mediated by intracellular viral proteins. Induction of oncogenic signals
(BCL-2, IL-2, IL-10, sIL-2R) and reduced sensitivity to Fas-induced apoptosis
(decreased levels of caspases 3/7 and caspase 9). (C) Permanent genetic B-cell
damage, e.g., mutation of tumor suppressor genes, (p53, BCL-6, beta-catenin)
caused by a transiently intracellular virus – the so called ‘‘hit and run’’ theory.
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common antigenic epitope, leading to selection and expansion of
a B-cell clone, which might consecutively be the origin of overt
HCV-NHL. Quinn et al. provided evidence that the mentioned
common antigen may indeed be HCV [63]. The group cloned the
BCR from two HCV positive DLBCL cases and tested the receptor
ability to bind to HCV E2. The rescued immunoglobulin was
shown to bind to the HCV-E2 glycoprotein in a manner identical
to a bona ﬁde human anti-E2 antibody. Moreover, immortalized
B cells from HCV positive patients selected for binding to E2 have
been shown to preferably express VH1-69 genes [64]. Similarly, in
a reported case of HCV-associated plasma cell leukemia, immuno-
blotting showed that the monoclonal IgG-kappa detected in the
serumwas directed against HCV core protein [65]. These data sup-
port the hypothesis of an indirect, antigen-driven lymphoma
development caused by HCV proteins in analogy to H. pylori trig-
gered MALT lymphoma. The clinical knowledge that HCV infected
patients with MC are at higher risk to develop HCV-NHL [13] and
the identiﬁcation of oligoclonal cell populations in MC patients
with consecutive development of NHL [66] lead to the theory that
MC could be an intermediary step to the development of malig-
nant transformation to HCV-NHL. Towards overt lymphoma there
might be an additional event (‘‘second hit’’) needed, possibly a
genomic alteration, such as a mutation or the antiapoptotic Bcl-
2 rearrangement, a translocation t(14;18), which has been found
associated with MC andMALT lymphoma in patients with chronic
HCV infection [67–70].
It is still unclear which signals or signaling pathways mediate
HCV-NHL oncogenic transformation. The proinﬂammatory inter-
leukin 6 (IL-6) with known strong stimulatory effect on B cells
has been suggested to contribute to the development of cryoglob-
ulinemia and B-NHL [71]. Furthermore, upregulation of the B-lym-
phocyte stimulator factor (BLyS) may play a role in MC and HCV-
NHL [72–75]. Transgenic mice overexpressing BLyS develop B-cell
hyperproliferation together with production of high levels of
immunoglobulins, rheumatoid factor, and cryoglobulins [76].
BLyS is a potent co-activator of immunoglobulin production and
activates NF-jB, JNK, and ERK pathways consecutively leading to
B-cell survival and proliferation. Activation of the BLys-receptor
provides an accumulation of p52 protein deriving from p100,
which activates NF-jB via the non-canonical pathway [77].
MicroRNAs (miRNAs) are short non-coding RNAs that bind to
complementary sites of target mRNAs and can modulate gene
expression by either translational repression or mRNA
degradation. A reduced expression of miR-26b has been found in
HCV positive versus HCV negative patients with SMZL [78]. The
diminished expression of miR-26b, as seen in the HCV positive
lymphomas, has demonstrated oncogenic potential in vitro and
has been linked to amalignant tumor phenotype in hepatocellular
carcinoma and lung carcinoma. One predicted target ofmiRNA26b
is the NIMA-related kinase NEK6, which has a critical role in
mitotic cell cycle progression and is upregulated in various human
cancers [79].
The concept of direct oncogenic effects by HCV replication in B
cells has been a matter of debate. HCV infection of lymphocytes,
e.g., peripheral blood mononuclear cells (PBMC), is supported by
various studies [51]; but active replication of HCV in human lym-
phocytes in vivo, with evidence of HCV-RNA negative strands, the
viral replicative intermediates, has been demonstrated in some
studies but not all [80,81]. In particular, active viral replication
could not be demonstrated in HCV-NHL tissue [82]. One
explanation for these contradictory ﬁndings could be that HCVJournal of Hepatology 201replication is conﬁned to certain rare subsets of B cells, e.g., CD5+
cells [83], or another event could beneeded tomakeB cells permis-
sive for HCV infection, such as EBV infection [84]. Moreover, one
study found that peripheral blood B cells from patients with
chronic HCV infection were indeed infected and simultaneously
showed enhanced gene expression associated with B-NHL [85].3 vol. 59 j 169–177 173
Key Points
• The risk to develop B-NHL is moderately increased in
chronic HCV (RR 2-3) and the molecular mechanisms
of HCV-NHL development are still poorly understood
• First-line AVT for indolent HCV-NHL may be a viable
option while aggressive HCV-NHL should primarily be
subject to standard immune-chemotherapy
• Systemic chemotherapy of HCV-NHL should be
accompanied by close monitoring of hepatic function
and an interdisciplinary collaboration between
hematologists and hepatologists is essential for optimal
treatment of HCV-NHL
• Post-remission HCV eradication after successful
immuno-chemotherapy of DLBCL might be considered
to prevent recurrence
• Inclusion of HCV-NHL patients in prospective studies
is encouraged, as the number of systematic studies
is still limited. New studies are needed to gauge the
efficacy of triple antiviral therapy and upcoming IFN-
free regimens in HCV-NHL
ReviewIn vitro, HCV replication in B cells has been impressively dem-
onstrated by Sung et al. who established an HCV infected B-NHL
cell line (SB cells), whose virions can infect primary human hepa-
tocytes, PBMCs, and a B-cell line (Raji cells) in vitro [49]. Despite
the fact that lymphotropic HCV replication may still be uncertain,
there is ample evidence that intracellular virus proteins could
contribute to oncogenic transformation. For instance, interferon
regulatory factor-1-null (irf-1/) mice with inducible and persis-
tent expression of HCV structural proteins (irf-1//CN2 mice)
show a high incidence of lymphomas and lymphoproliferative
disorders [86]. In this model, overexpression of apoptosis-related
proteins and aberrant cytokine production were the primary
events found to induce lymphoproliferation. Another transgenic
mouse expressing HCV core protein showed frequent develop-
ment of follicular center cell type lymphoma (80% at >20 month
of age), with HCV core mRNA detected in lymphoma tissue
[87]. Another very interesting mouse model was established by
Kasama et al. [88]. The Japanese group created HCV transgenic
mice that expressed the full HCV genome in B cells (RzCD19Cre
mice). Notably, RzCD19Cre mice developed DLBCL with a signiﬁ-
cantly higher frequency compared to their genetically identical
counterpart without HCV expression (CD19Cre- or RzCD19 mice).
A possible transforming mechanism could involve serum-soluble
interleukin-2 receptor a-subunit (sIL-2Ra), which was found in
substantially elevated levels in RzCD19Cre mice [89].
As third concept of HCV-NHL development, a ‘‘hit and run’’
mechanism has been proposed to explain possible transforming
B-cell damage without evidence of virus replication inside tumor
cells. Machida et al. found HCV to induce a high mutation fre-
quency of cellular genes (immunoglobulin heavy chain, Bcl-6,
p53 and beta-catenin) in vitro by inducing double strand breaks
and by activating error-prone polymerases and AID [90]. The
authors suggested that HCV induces amutator phenotype by caus-
ing alterations in proto-oncogenes and tumor suppressor genes,
which consecutively lead to oncogenetic transformation of B cells,
although the virus may have already left the cell. There remains174 Journal of Hepatology 201some doubt about the clinical applicability of these ﬁndings as
others were not able to conﬁrm these ﬁndings in vivo [91,92].Conclusions and perspectives
Cumulative epidemiologic evidence supports the thesis that
patients with chronic HCV infection are at increased risk to
develop lymphoma. The strength of the association of HCV and
B-NHL varies greatly with the geographic location. The molecular
mechanisms of HCV-associated lymphomagenesis are still poorly
understood. There are different hypothetical concepts of the trans-
formational process deriving from studies in vitro and in vivo.
These theories do not necessarily stand in competition with each
other, but could be parallel pathways leading to HCV-NHL, as a
combination of transforming events might well be needed to
result in overt lymphoma. Bridging studies that connect concepts
from functional experiments to the in vivo condition are needed.
Interventional studies on treatment of HCV-NHL with AVT show
promising rates of remission in indolent lymphoma subtypes.
Findings of a close relation of virologic and lymphoma response
raise hope that with high SVR rates of emerging new antiviral
drugs, HCV-NHL therapy might improve further.Conﬂict of interest
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